Carving Out Olyrian Diagnostics Ahead Of A Complete 2028 Separation
In an official strategic roadmap released from Erlangen, Siemens Healthineers confirmed it has begun the structural separation of its clinical laboratory diagnostics business. Handling more than 16 billion lab tests annually across international medical networks, the operational division will formally operate under the brand name Olyrian Diagnostics throughout the transition phase before completing an absolute corporate divestment or initial public offering by mid-2028.
The diagnostics arm represents nearly 17% of group sales while employing 20% of the company's global workforce. The strategic divestment follows underwhelming fourth-quarter figures where adjusted earnings before interest and tax (EBIT) margins stagnated at 5.4%, prompting the executive board to moderate growth projections for fiscal 2027.
The planned separation will create near-term carve-out and stranded costs but result in a more focused business over the longer term
















